Hemostatic and antifibrinolytic agent
PCP: Signs of shock or hypoperfusion, in association with an injury suggestive of occult or ongoing hemorrhage
PCP: Signs of shock or hypoperfusion in maternal vaginal bleeding >20 weeks or postpartum hemorrhage
PCP: Signs of shock or hypoperfusion in association with an injury suggestive of occult or ongoing hemorrhage
PCP: Signs of shock or hypoperfusion in maternal vaginal bleeding >20 weeks or postpartum hemorrhage
ACP: Signs of shock or hypoperfusion in association with an injury suggestive of occult or ongoing hemorrhage
Vial: 100 mg/mL (500 mg in 5 mL vial)
May also be supplied as 1,000 mg in 10 mL vial (100 mg/mL)
Prevents clot degradation by competing for TPA receptor sites.
Intravenous:
May potentiate hypotension if administered too quickly
For intravenous use only. Do not administer intramuscularly or subcutaneously.